Skip to content

D&A at other companies

Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$79K+3.9%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$151K-64.6%
Immunome logo
ImmunomeIMNM
$603K-1.3%
Vor Biopharma logo
Vor BiopharmaVOR
$28K-96.6%
Annexon logo
AnnexonANNX
$539K+0.4%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$2M-33.3%

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$765.73M+307%
P/S8.5×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Reported directly by Omeros in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Omeros’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omeros's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omeros's D&A?
Omeros (OMER) reported D&A of $239K in Q1 2026.
How has Omeros's D&A changed year-over-year?
Omeros's D&A decreased by 17.3% year-over-year, from $289K to $239K.
What is the long-term trend for Omeros's D&A?
Over 4 years (2021 to 2025), Omeros's D&A has grown at a -9.1% compound annual growth rate (CAGR), from $1.41M to $964K.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.